Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
Abstract
Objective: To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Design: Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks. Setting: 23 academic asthma centres in United States, Canada, and Europe. Participants: 226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo). Interventions: Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised clinical score. Main outcome measures: Last tolerated dose of inhaled corticosteroids. Results: Compared with placebo, montelukast allowed significant (P=0.046) reduction in the inhaled corticosteroid dose (montelukast 47% v placebo 30%; least square mean difference 17.6%, 95% confidence interval 0.3 to 34.8). Fewer patients on montelukast (18 (16%) v 34 (30%) placebo, P=0.01) required discontinuation because of failed rescue. Conclusions: Montelukast reduces the need for inhaled corticosteroids among patients requiring moderate to high doses of corticosteroid to maintain asthma control. Leukotriene receptor antagonists have complementary action to inhaled corticosteroids in asthma Many patients receive higher doses of inhaled corticosteroids than clinically required In this placebo controlled trial, montelukast allowed significant reduction of inhaled corticosteroid doses Fewer patients receiving montelukast had failed rescue than patients receiving placeboKeywords
This publication has 19 references indexed in Scilit:
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Use of Inhaled Corticosteroids and the Risk of CataractsNew England Journal of Medicine, 1997
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997
- Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1996
- Issues in the Use of Inhaled Glucocorticoids. The Asthma Clinical Research NetworkAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Standardization of Spirometry, 1994 Update. American Thoracic SocietyAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Adverse effects of inhaled corticosteroidsThe American Journal of Medicine, 1995
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Effect of Oral Prednisone on Airway Inflammatory Mediators in Atopic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1994